Patent US4769331A successfully refreshed from Google Patents.
US4769331A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant methods and materials
Assignee: University Patents Inc
•
Filing: 1985-01-09
•
Granted: 1988-09-06
•
Expires: 2005-01-09
Abstract
Abstract Specific DNA sequence insertions, deletions and substitutions (i.e., combinations of sequence deletion and insertion) in eukaryotic cell or viral genomes are stably effected through use of selectable DNA sequences comprising a herpesvirus thymidine kinase (tk) gene.
Inventors
- 👤 Bernard Roizman
- 👤 Leonard E. Post
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 09:11
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/87; C12N15/90; C12N15/902
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
191 words
A method for stably effecting the insertion or deletion of a selected DNA sequence at a specific site in a viral genome, said method comprising: (1) isolating from said genome a linear DNA fragment comprising both (a) the specific site determined for insertion or deletion of selected DNA sequence and (b) flanking DNA sequences normally preceding and following said site; (2) preparing first and second altered genome fragments from the fragment isolated in step (1). (a) said first altered fragment comprising the fragment comprising a thymidine kinase gene in a position intermediate the ends of said fragment, and (b) said second altered fragment comprising the fragment having said selected DNA sequence inserted therein or deleted therefrom; (3) contacting said genome with said first altered fragment under conditions permitting recombination at sites of DNA sequence homology, selecting for a recombinant genome comprising said thymidine kinase gene, and isolating the recombinant genome; and (4) contacting the recombinant genome isolated in step (3) with said second altered fragment under conditions permitting recombination at sites of DNA sequence homology, selecting for a recombinant genome lacking said thymidine kinase gene, and isolating the recombinant genome product.
Claim 2
Independent Claim
191 words
A method for stably effecting the insertion or deletion of a selected DNA sequence at a specific site in a viral genome, said method comprising: (1) isolating from said genome a linear DNA fragment comprising both (a) the specific site determined for insertion or deletion of selected DNA sequence and (b) flanking DNA sequences normally preceding and following said site; (2) preparing first and second altered genome fragments from the fragment isolated in step (1). (a) said first altered fragment comprising the fragment comprising a thymidine kinase gene in a position intermediate the ends of said fragment, and (b) said second altered fragment comprising the fragment having said selected DNA sequence inserted therein or deleted therefrom; (3) contacting said genome with said first altered fragment under conditions permitting recombination at sites of DNA sequence homology, selecting for a recombinant genome comprising said thymidine kinase gene, and isolating the recombinant genome; and (4) contacting the recombinant genome isolated in step (3) with said second altered fragment under conditions permitting recombination at sites of DNA sequence homology, selecting for a recombinant genome lacking said thymidine kinase gene, and isolating the recombinant genome product.
Claim 3
Dependent Claim
14 words
The method according to claim 1 wherein the genome is a pathogenic viral genome.
Claim 4
Dependent Claim
18 words
The method according to claim 1 wherein said thymidine kinase gene is of human Herpes Virus 1 origin.
Claim 5
Dependent Claim
34 words
The method according to claim 1 wherein the step of selecting for a recombinant genome comprising said thymidine kinase gene comprises the step of exposing the recombinant genome to a growth medium comprising HAT.
Claim 6
Independent Claim
37 words
The method according to claims 1 or 4 wherein the step of selecting for a recombinant genome not comprising said thymidine kinase gene comprises the step of exposing the recombinant genome to a growth medium comprising AraT.
Claim 7
Dependent Claim
31 words
The method according to claim 1 wherein the method comprises the step of deleting one selected DNA sequence and wherein the method comprises the step of inserting another selected DNA sequence.
Claim 8
Dependent Claim
22 words
The method according to claim 6 wherein said deleting and inserting steps are effected at substantially the same site in the genome.
Claim 9
Dependent Claim
20 words
The method according to claim 6 wherein said deleting and inserting steps are effected at different sites in the genome.
Claim 10
Dependent Claim
15 words
The method according to claim 8 wherein the DNA sequences inserted and deleted are identical.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-06 | 1992-03-07 | 1992-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-06 | 1996-03-07 | 1996-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-06 | 2000-03-07 | 2000-09-06 | $7700.00 | Window Closed / Lapsed |